MedTrace Logo

CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

NCT00973505 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-09-09

No results posted yet for this study

Summary

The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.

Conditions

Interventions

DRUG

Aromatase Inhibitor(Femara or Arimidex)

Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd

Sponsors & Collaborators

  • Korea University

    collaborator OTHER

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Eun Sook Lee, MD, PhD · Korea University Anam Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973505 on ClinicalTrials.gov